ClinicalTrials.gg
RecruitingNCT05577988ADENUpdated Jan 16, 2026

Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

A Phase 3 interventional study of single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing. in MYOCARDIAL INFARCTION, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,468
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, 2 of them phase 3. Myocardial Infarction · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
3rd of 12
2,468 · median 1,136
Started
2024
the only one that year
Phase 3
7 of 16
2 open now
Registered
16th of 16
by date

Among the 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 3, and was the 16th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

4 of the 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Patients who suffered from acute coronary syndrome (ACS) are usually treated with a long-term dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic event. Nonetheless, recent important data have demonstrated the efficacy of a short term DAPT and an early single antiplatelet therapy in high bleeding and ischemic risk patients.

The bleeding risk is associated with a significant mortality. This risk is especially high in patients treated with potent P2Y12 inhibitors like ticagrelor or prasugrel after an ACS.

As a result of the abounding data regarding the safety of an early single antiplatelet therapy with high potency antiplatelet therapy (ticagrelor or prasugrel), it is likely that such strategy will soon be implemented in the guidelines.

The benefits of these high-potency P2Y12 inhibitors over clopidogrel mostly occur in patients with genetic polymorphisms of CYP2Y12 associated with a loss of function in clopidogrel metabolism.

Furthermore, the anti-ischemic benefit of potent P2Y12 inhibitors over clopidogrel occurs early, while excess bleeding events often arise during chronic treatment.

Our hypothesis is that a systematic and rapid genetic screening of CYP2C90 *2 or *17 polymorphism to guide an early single therapy with low potency antiplatelet (aspirin or clopidogrel) could lead to less bleeding events with a consistent efficacy towards cardiac events compared with high potency antiplatelet therapies (prasugrel or ticagrelor) in high bleeding risk patients treated for ACS.

Read the detailed description

Multicenter, randomized, open label trial using the PROBE study design. Randomization 1 to 3 months (preferably 1, considering the HBR) after ACS into 2 parallel arms. Stratification: according to revascularization status (PCI or no PCI), genotype (loss of function, fast metabolization, none) and center.

Control arm: stop aspirin for a single antiplatelet therapy with a high-potency antiplatelet (ticagrelor or prasugrel).

Intervention arm: single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

03

Conditions studied

  • MYOCARDIAL INFARCTION

Keywords

  • Acute Coronary Syndrome
  • High Bleeding Risk
  • Antiplatelet Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 18-year-old or older
  • Admission for type 1 acute myocardial infarction (STEMI or NSTEMI)
  • Bedside genetic testing for clopidogrel resistance that can be performed during hospital stay for ACS (oral swab kit with result within 1 hour)
  • Treated with aspirin and ticagrelor, or aspirin and prasugrel at the screening phase and at the randomization visit.
  • High bleeding risk as defined below (criteria adapted from the Consensus Document From the Academic Research Consortium for High Bleeding Risk) (at least one criterion) :

    • Age ≥75 years old.
    • Baseline \<11 g/dl (or anaemia requiring transfusion during the 4 weeks prior to randomization).
    • Chronic Kidney Disease with estimated ≤ 30 ml/min.
    • Thrombocytopenia with count \< 100 x 109 / L
    • Chronic bleeding diatheses: inherited or acquired conditions known to be associated with increased bleeding risk such as platelet dysfunction, von Willebrand disease (prevalence of 1%-2% in the general population), inherited or acquired clotting factor deficiencies (including factors VII, VIII [hemophilia A], IX [hemophilia B], and XI), or acquired antibodies to clotting factors, among others.
    • Cirrhosis with portal hypertension.
    • PCI after major traumatism or surgery.
    • Any documented stroke in the last 12 months.
    • Hospital admission for bleeding or transfusion within last 6 months.
    • Nonskin cancer diagnosed or treated ≤3 years.
    • Planned daily nonsteroidal anti-inflammatory drugs (other than aspirin) or for ≥30 days after PCI.
  • patient affiliated to a social security system
  • signed form
  • Women of childbearing capacity with effective for the duration of the research OR man, OR woman not of childbearing capacity

Exclusion criteria

Exclusion Criteria:

  • Currently participating in any interventional device or drug trial
  • Any prior documented intracerebral bleed
  • , known allergy or expected interactions with clopidogrel. Baseline treatment (at screening) should not include an antiplatelet therapy for which a contra-indication, known allergy or expected interactions is known (example history of stroke and use of prasugrel, or concomitant use of ticagrelor and ritonavir)
  • Patients on concomitant treatment with an anticoagulant agent (Vitamin-K antagonists or novel oral anticoagulants such as rivaroxaban, dabigatran or apixaban)
  • Planned surgery within 12 coming months
  • Patient under guardianship or curatorship
  • Pregnancy or breastfeeding
  • Inability to sign the form
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,468 participants (estimated)

Study arms

  • No intervention
    Control arm

    Standard of Care : Systematic de-escalation to a high potency antiplatelet single therapy

  • Other
    Intervention arm

    single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

    Other: single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

Interventions

  • Othersingle-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

    * Individuals without genetic loss of function to metabolize clopidogrel (\*1/\*1, \*2/\*17, \*3/\*17): stop DAPT and switch to a single antiplatelet therapy by clopidogrel. * Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2,\*3/\*3): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin. * Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.

06

What researchers measure

Primary outcomes

  1. Rate of combinated major and minor bleeding events (BARC 2 to 5 BARC)

    the occurrence of major or minor bleeding events between randomization to one of the de-escalation strategies and 1 year after index ACS defined according to the Bleeding Academic Research Consortium (BARC) classification as type 2 to 5

    Time frame: From randomization (1-3months after inclusion) to 1year after inclusion

Secondary outcomes

  1. Rate of major adverse cardiovascular events

    major adverse cardiovascular events defined as follow and in the following hierarchical order: * Death or myocardial infarction or stroke or stent thrombosis (key secondary) * Death or Myocardial infarction

    Time frame: From randomization to de-escalation (1-3months) to 1year

  2. Rate of major bleeding events

    the occurrence of major bleeding events between randomization to one of the de-escalation strategies and 1 year after index ACS defined according to the Bleeding Academic Research Consortium (BARC) classification

    Time frame: randomization to de-escalation (1-3months) to 1year

  3. Rate of minor bleeding events

    the occurrence of minor bleeding events between randomization to one of the de-escalation strategies and 1 year after index ACS defined according to the Bleeding Academic Research Consortium (BARC) classification

    Time frame: randomization to de-escalation (1-3months) to 1year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

Of 34 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's planned 36 months is below that.

Counting every sponsor, half of 58 studies reached it within 44 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 13, 2022
StartActual
Jun 18, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05577988
Collaborators
Fonds de Dotation ACTION
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Jun 18, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Michel ZEITOUNI, MD,PhD
Contact
michel.zeitouni@aphp.fr
33142165535
Delphine BRUGIER, PhD
Contact
delphine.brugier-ext@aphp.fr
33142162918
Michel ZEITOUNI, MD, PhD
study chair · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion